Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?

Enliven Therapeutics, Inc. (ELVN) closed the last trading session at $22.20, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35.25 indicates a 58.8% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $3.77. While the lowest estimate of $32 indicates a 44.1% increase from the current price level, the most optimistic ...